NCT00635713View on ClinicalTrials.gov

Second Line Breast Cancer Trial

PHASE3CompletedINTERVENTIONAL

Enrollment

588

Participants

Timeline

Start Date

May 31, 1997

Study Completion Date

September 30, 2004

Conditions

Advanced Breast Cancer

Interventions

DRUG

Fulvestrant

125mg

DRUG

Anastrozole

ARIMIDEX

DRUG

Fulvestrant

250mg

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY